You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Anti-COVID-19 measurements for hidradenitis suppurativa patients
Copyright policy )Anti-COVID-19 measurements for hidradenitis suppurativa patients
Abstract The reported incidence of COVID‐19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID‐19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID‐19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti‐COVID‐19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS‐CoV2 and patients affected by metabolic syndrome constitute a high‐risk group for COVID‐19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non‐living virus anti‐SARS‐CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.
Microsoft Academic Graph classification: medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severity of illness medicine Adalimumab Hidradenitis suppurativa Anakinra business.industry Incidence (epidemiology) medicine.disease Dermatology Metabolic syndrome business Cohort study medicine.drug
SARS‐CoV2, COVID-19 Vaccines, Supplement Articles, Dermatology, Biochemistry, Severity of Illness Index, Cohort Studies, SDG 3 - Good Health and Well-being, COVID‐19, vaccine, Correspondence, Humans, Molecular Biology, Pandemics, Metabolic Syndrome, 10th European Hidradenitis Suppurativa (EHSF) e.V. Conference, SARS-CoV-2, Incidence, Adalimumab, COVID-19, Hidradenitis Suppurativa, Europe, Interleukin 1 Receptor Antagonist Protein, Supplement Article, Disease Susceptibility, Foundations
SARS‐CoV2, COVID-19 Vaccines, Supplement Articles, Dermatology, Biochemistry, Severity of Illness Index, Cohort Studies, SDG 3 - Good Health and Well-being, COVID‐19, vaccine, Correspondence, Humans, Molecular Biology, Pandemics, Metabolic Syndrome, 10th European Hidradenitis Suppurativa (EHSF) e.V. Conference, SARS-CoV-2, Incidence, Adalimumab, COVID-19, Hidradenitis Suppurativa, Europe, Interleukin 1 Receptor Antagonist Protein, Supplement Article, Disease Susceptibility, Foundations
Microsoft Academic Graph classification: medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severity of illness medicine Adalimumab Hidradenitis suppurativa Anakinra business.industry Incidence (epidemiology) medicine.disease Dermatology Metabolic syndrome business Cohort study medicine.drug
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10% citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!- University of Ferrara Italy
- Université Libre de Bruxelles Belgium
- University of Copenhagen Denmark
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Italy
- University of Milan Italy
- Erasmus University Medical Center Netherlands
- National and Kapodistrian University of Athens Greece
Abstract The reported incidence of COVID‐19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID‐19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID‐19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti‐COVID‐19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS‐CoV2 and patients affected by metabolic syndrome constitute a high‐risk group for COVID‐19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non‐living virus anti‐SARS‐CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.